Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced that its lead candidate for treating concussion, ONP-002, does not cause DNA damage and genotoxicity in an animal model. According to the announcement, the company completed a study evaluating ONP-002, a new chemical entity (“NCE”) designed to target the brain through delivery into the nasal cavity and onward to the brain. Testing on cells and animals to ensure a substance does not cause damage affecting cell division is required by the U.S. Food and Drug Administration prior to conducting a clinical trial.
“We continue to be pleased with the safety profile of ONP-002,” said Oragenics president Michael Redmond in the press release. “We have now shown a safety margin in our two-species toxicology program, cardiac safety with GLP hERG testing and no issue with cancer-causing DNA damage using the in vivo micronucleus assay. Oragenics strongly believes that ONP-002 will be safe for concussed patients in our planned phase 2 clinical trial. We will continue to monitor systemic and intranasal safety parameters throughout the drug-development program.”
To view the full press release, visit https://ibn.fm/RRdj4
About Oragenics Inc.
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as proprietary powder formulation and an intranasal delivery device. For more information about the company, please visit www.Oragenics.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN